XML 31 R20.htm IDEA: XBRL DOCUMENT
v3.20.2

Revenues (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2020
Segment Reporting [Abstract] |
Summary of net revenue | The Company’s net revenues consisted of the following for the three and nine months ended September 30, 2020 and 2019:
| Three months ended September 30, |  | Nine months ended September 30,
| 2020 |  | 2019 |  | 2020 |  | 2019
Products: |  |  |  |  |  |  |
Acetadote | $ | 218,462 |  |  | $ | 777,185 |  |  | $ | 1,527,173 |  |  | $ | 2,608,160 |
Omeclamox-Pak | 516,066 |  |  | 116,063 |  |  | 640,435 |  |  | 794,205 |
Kristalose | 3,615,557 |  |  | 2,924,237 |  |  | 10,387,046 |  |  | 9,720,434 |
Vaprisol | 406,162 |  |  | 224,940 |  |  | 790,817 |  |  | 724,143 |
Caldolor | 1,416,146 |  |  | 1,170,567 |  |  | 3,677,434 |  |  | 3,543,166 |
Vibativ | 2,813,249 |  |  | 1,451,595 |  |  | 8,551,125 |  |  | 6,156,653 |
Other revenue | 265,047 |  |  | 270,852 |  |  | 1,605,570 |  |  | 1,535,981 |
Total net revenues | $ | 9,250,689 |  |  | $ | 6,935,439 |  |  | $ | 27,179,600 |  |  | $ | 25,082,742 |

X
- Definition Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 + Details
Name: | us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration